Alphamab Oncology Dividend

Dividend criteria checks 0/6

Alphamab Oncology does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield1.1%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-HK$0.22
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05
Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Feb 09
How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?

Dec 30
Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?

What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?

Nov 25
What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 9966's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 9966's dividend payments have been increasing.


Dividend Yield vs Market

Alphamab Oncology Dividend Yield vs Market
How does 9966 dividend yield compare to the market?
SegmentDividend Yield
Company (9966)n/a
Market Bottom 25% (HK)3.1%
Market Top 25% (HK)7.5%
Industry Average (Biotechs)1.1%
Analyst forecast in 3 Years (9966)0%

Notable Dividend: Unable to evaluate 9966's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 9966's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate 9966's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 9966 has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.